A Phase I Trial of Dinaciclib (SCH727965) and MK-2206 in Metastatic Pancreatic Cancer With an Expansion Cohort in Advanced Pancreatic Cancer
Phase of Trial: Phase I
Latest Information Update: 24 Aug 2017
Price : $35 *
At a glance
- Drugs Dinaciclib (Primary) ; MK 2206 (Primary)
- Indications Pancreatic cancer
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 21 Aug 2017 Status changed from active, no longer recruiting to completed.
- 03 Aug 2016 Status changed from recruiting to active, no longer recruiting.